Pfizer announcing this morning, they will stop development of
their experimental obesity and type two diabetes drug Ron due
to the risk of liver damage. Patients who took
the pill during clinical trials showed elevated liver enzymes.
Pfizer said no patients experienced liver problems or side effects
. Instead, the drug maker is focusing its efforts
on another oral treatment for obesity, which is currently
in phase two clinical trials. According to data released
by Pfizer, their drug had similar weight loss results
to Novo Nordisk.